Smell Loss
Clinical Trial
Condition: Hyposmia
Loss of Smell Research
A Randomized, Double-Blinded, Placebo-Controlled Trial to Determine The Safety and Efficacy of CYR-064
The purpose of this loss of smell research study is to evaluate the safety and effectiveness of CYR-064 in a randomized, double-blinded, placebo-controlled trial. This clinical trial aims to explore CYR-064 as a potential treatment for hyposmia, the partial loss of smell. The study will assess both the safety and efficacy of the treatment, contributing to the growing body of research on smell disorders.
The study spans approximately 32 weeks, beginning with a 4-week screening period. During this period, potential participants are evaluated to ensure they meet the eligibility criteria. This thorough screening includes medical assessments and tests to confirm their condition and ensure that the data collected will be relevant and accurate. Eligible participants then proceed to the treatment phase.
The 24-week treatment period is the core of the study of the olfactory system dysfunction. Participants are randomly assigned to receive either CYR-064 or a placebo, maintaining a double-blinded approach so that neither participants nor researchers know who is receiving the treatment. This method is essential to produce unbiased results. During the treatment period, participants will be regularly monitored, with clinical evaluations to assess any changes in their sense of smell and track the safety of CYR-064. The effectiveness of the treatment will be measured through standardized smell tests and quality-of-life questionnaires.
After the treatment period, there is a 1-week follow-up. This stage allows researchers to observe any residual effects and ensure that participants’ health is stable after the study. The data collected during the follow-up will further inform the safety profile of CYR-064.
The study involves about 150 subjects across approximately 25 research sites in the United States, offering a diverse and comprehensive participant base. By participating, individuals will contribute to important research on potential new treatments for hyposmia, a condition that significantly impacts daily life.
This loss of smell research aims to address the limited treatment options for smell disorders by generating valuable data on CYR-064’s safety and effectiveness. Through this trial, researchers hope to move closer to an effective treatment for those experiencing hyposmia and improve their quality of life.
ACTIVELY ENROLLING SMELL LOSS TRIAL
Smell Loss Study Location: Colorado Springs, CO
Colorado ENT and Allergy
Smell Loss Study Location: Bethlehem, PA
Specialty Physician Associates